Holst_2008_Trends.Mol.Med_14_161

Reference

Title : Glucagon-like peptide-1, glucose homeostasis and diabetes - Holst_2008_Trends.Mol.Med_14_161
Author(s) : Holst JJ , Deacon CF , Vilsboll T , Krarup T , Madsbad S
Ref : Trends Mol Med , 14 :161 , 2008
Abstract :

Incretins, enhancers of insulin secretion, are essential for glucose tolerance, and a reduction in their function might contribute to poor beta-cell function in patients with type-2 diabetes mellitus. However, at supraphysiological doses, the incretin glucagon-like peptide-1 (GLP-1) protects pancreatic beta cells, and inhibits glucagon secretion, gastric emptying and food intake, leading to weight loss. GLP-1 mimetics, which are stable-peptide-based activators of the GLP-1 receptor, and incretin enhancers, which inhibit the incretin-degrading enzyme dipeptidyl peptidase-4, have emerged as therapies for type-2 diabetes and have recently reached the market. The pathophysiological basis the clinical use of these therapeutics is reviewed here.

PubMedSearch : Holst_2008_Trends.Mol.Med_14_161
PubMedID: 18353723

Related information

Citations formats

Holst JJ, Deacon CF, Vilsboll T, Krarup T, Madsbad S (2008)
Glucagon-like peptide-1, glucose homeostasis and diabetes
Trends Mol Med 14 :161

Holst JJ, Deacon CF, Vilsboll T, Krarup T, Madsbad S (2008)
Trends Mol Med 14 :161